A brand new class of epilepsy medicines primarily based on an ingredient derived from marijuana might be accessible as quickly as within the second half of 2018 within the United States pending Food and Drug Administration approval.

Officials from GW Pharmaceuticals, the corporate that developed the drug, on Wednesday introduced promising outcomes from a research on 171 sufferers randomized into remedy and placebo teams.

Members of the group, who have been 2 to 55 years of age, have a situation known as Lennox-Gastaut Syndrome and have been affected by seizures that weren’t being managed by current medication. 

Click here to read the complete article

MagNerd.com via 420Intel.com

Recent News Articles

Friday August 23

Napa County Ballot to Include Initiative for Commercial Cannabis Cultivation

in U.S. News

by Mike Fuller

Will wine tasters be set off their cabernet sauvignon should Napa County decide to allow…

180 hits

Saturday August 24

California Says Its Cannabis Revenue Has Fallen Short Of Estimates, Despite Gains

in U.S. News

by Mike Fuller

California's cannabis excise tax generated only $74.2 million in the second quarter of 2019, the…

149 hits

Saturday August 24

CBD Companies Positioning Themselves For Cannabis Legalization

in Cannabis News

by Mike Fuller

Recreational cannabis use is illegal in the majority of US states, but the relaxation of…

586 hits

Monday August 26

DEA Announces It Will Finally Take Action On Marijuana Grower Applications - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

The Drug Enforcement Administration (DEA) announced on Monday that is is taking steps to expand…

123 hits

Monday August 26

How much pot in that brownie? Chocolate can throw off tests - Cannabis News

in Science

by Bruce Kennedy - Editor in Chief

Chocolate can throw off potency tests so labels aren’t always accurate, and now scientists are…

142 hits